Literature DB >> 9349461

Variations in the neutralizing and haemagglutination-inhibiting activities of five influenza A virus-specific IgGs and their antibody fragments.

D J Schofield1, J R Stephenson, N J Dimmock.   

Abstract

Neutralization and haemagglutination-inhibition (HI) of a type A influenza virus by a panel of five monoclonal IgGs, their F(ab')2s, Fabs and Fabs+ anti-mouse Fab were compared. The MAbs were specific for antigenic sites A, B and D of the haemagglutinin. Activities of the IgGs varied by up to 6-fold on a molar basis, apart from the HI activity of HC58 which was > 100-fold lower. This was not due to low functional affinity as HC58 had the second highest value (nM) as determined by an equilibrium method with whole virions. Conversion to the F(ab')2 reduced neutralization and HI by only 2- to 6-fold, indicating that the Fc region had little involvement in these processes. However, all Fabs had low neutralization and HI activity compared with their IgGs, neutralization being reduced by 86 to > 1912-fold, and HI by 13 to > 69-fold. Although decreased, their affinities remained high, in the nM range. Neutralization and HI by three of the Fabs (HC2, HC3W and HC61) were restored by the addition of anti-Fab IgG; however, HC10 Fab+anti-Fab IgG still had no detectable neutralization activity but gave HI, and HC58 Fab+anti-Fab IgG had no detectable HI activity but neutralized to the same extent as its IgG. The different properties of the antibodies are discussed in the light of their known mechanisms of action: HI by steric blocking of attachment of virus to the red cell receptor, and neutralization by the inhibition of post-attachment events (HC2, HC10 and HC61). The data demonstrate just how variable are the antiviral properties of individual IgGs.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9349461     DOI: 10.1099/0022-1317-78-10-2431

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  19 in total

1.  Complement component C1q enhances the biological activity of influenza virus hemagglutinin-specific antibodies depending on their fine antigen specificity and heavy-chain isotype.

Authors:  Jing Qi Feng; Krystyna Mozdzanowska; Walter Gerhard
Journal:  J Virol       Date:  2002-02       Impact factor: 5.103

2.  Enhanced HIV-1 neutralization by antibody heteroligation.

Authors:  Hugo Mouquet; Malte Warncke; Johannes F Scheid; Michael S Seaman; Michel C Nussenzweig
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-04       Impact factor: 11.205

3.  Evaluation of diagnostic applications of monoclonal antibodies against avian influenza H7 viruses.

Authors:  Ming Yang; Alfonso Clavijo; Jill Graham; John Pasick; James Neufeld; Yohannes Berhane
Journal:  Clin Vaccine Immunol       Date:  2010-07-21

4.  Binding and neutralization efficiencies of monoclonal antibodies, Fab fragments, and scFv specific for L1 epitopes on the capsid of infectious HPV particles.

Authors:  Timothy D Culp; Christin M Spatz; Cynthia A Reed; Neil D Christensen
Journal:  Virology       Date:  2007-01-12       Impact factor: 3.616

5.  Examination of the contributions of size and avidity to the neutralization mechanisms of the anti-HIV antibodies b12 and 4E10.

Authors:  Joshua S Klein; Priyanthi N P Gnanapragasam; Rachel P Galimidi; Christopher P Foglesong; Anthony P West; Pamela J Bjorkman
Journal:  Proc Natl Acad Sci U S A       Date:  2009-04-16       Impact factor: 11.205

6.  Evaluation of CD4-CD4i antibody architectures yields potent, broadly cross-reactive anti-human immunodeficiency virus reagents.

Authors:  Anthony P West; Rachel P Galimidi; Christopher P Foglesong; Priyanthi N P Gnanapragasam; Joshua S Klein; Pamela J Bjorkman
Journal:  J Virol       Date:  2010-01       Impact factor: 5.103

7.  Intra-spike crosslinking overcomes antibody evasion by HIV-1.

Authors:  Rachel P Galimidi; Joshua S Klein; Maria S Politzer; Shiyu Bai; Michael S Seaman; Michel C Nussenzweig; Anthony P West; Pamela J Bjorkman
Journal:  Cell       Date:  2015-01-29       Impact factor: 41.582

8.  Relating influenza virus membrane fusion kinetics to stoichiometry of neutralizing antibodies at the single-particle level.

Authors:  Jason J Otterstrom; Boerries Brandenburg; Martin H Koldijk; Jarek Juraszek; Chan Tang; Samaneh Mashaghi; Ted Kwaks; Jaap Goudsmit; Ronald Vogels; Robert H E Friesen; Antoine M van Oijen
Journal:  Proc Natl Acad Sci U S A       Date:  2014-11-17       Impact factor: 11.205

Review 9.  To dream the impossible dream: universal influenza vaccination.

Authors:  Jonathan W Yewdell
Journal:  Curr Opin Virol       Date:  2013-07-05       Impact factor: 7.090

10.  Few and far between: how HIV may be evading antibody avidity.

Authors:  Joshua S Klein; Pamela J Bjorkman
Journal:  PLoS Pathog       Date:  2010-05-27       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.